Whilst showing robust and durable immune protection in cancer patients, the clinical benefits of CTLA4 blockade are often overshadowed by severe immunotherapy-related adverse events (irAEs) that highly resemble autoimmune reactions (Martins et al., 2019; Postow et al., 2018). Here, CTLA4 is linked to cancer.